Alle Studien
Aktiv, aber nicht rekrutierendPHASE2INTERVENTIONELL

Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis

Ulcerative colitis is a long-term condition that causes inflammation and sores in the lining of the large bowel. While treatments are available, they do not work for everyone, leaving many people with ongoing stomach pain, frequent toilet visits, and bleeding. This Phase 2 trial is investigating a new medicine called emvistegrast (previously known as GS-1427). The main aim is to find out if emvistegrast is safe and effective in calming bowel inflammation in adults with moderate to severe ulcerative colitis. Participants will be placed into groups by chance to receive either emvistegrast or an inactive dummy treatment (placebo). Doctors will closely check their bowel symptoms, overall health, and gut healing over 12 weeks to see whether the new medicine provides clear benefits compared to the placebo.

Auf einen Blick

Status
Aktiv, aber nicht rekrutierend
Phase
PHASE2
Sponsor
Gilead Sciences
Einschreibeziel
228
Starten
27 Mar 2024
Geschätzte Fertigstellung
01 Apr 2028

Worum geht es in dieser Studie?

Ulcerative colitis is a chronic illness where parts of the large bowel become swollen and irritated. Living with an active flare-up can be difficult and exhausting, often causing frequent diarrhoea, stomach cramps, and extreme tiredness. While many people find relief with existing medications, these treatments can lose their effect over time or cause unwanted side effects. Finding new and better ways to control inflammation is essential.

This clinical trial is studying an experimental medicine called emvistegrast. Emvistegrast works by targeting specific proteins involved in the body's immune response, aiming to stop inflammation-causing cells from traveling into the bowel tissue. By calming this immune activity, researchers hope the medicine will help heal the lining of the bowel and relieve symptoms.

In this Phase 2 study, doctors are comparing emvistegrast to a placebo, which looks identical but contains no active drug. Comparing the two helps researchers prove whether any improvements in health are genuinely caused by the new medicine. The main results will be measured after 12 weeks of treatment to see if patients achieve a meaningful improvement in their symptoms and bowel inflammation.

Wichtige Erkenntnisse

  • The study tests a new medicine called emvistegrast for moderate to severe ulcerative colitis.
  • It is open to adults aged 18 to 75 whose previous colitis treatments did not work well enough.
  • Participants will receive either the study medicine or a dummy treatment (placebo).
  • Doctors will measure improvements in symptoms and bowel healing after 12 weeks.
  • Joining is entirely voluntary, and you can withdraw at any time without affecting your NHS care.

Wer könnte berechtigt sein?

This trial is designed for adults aged between 18 and 75 who have had ulcerative colitis symptoms for at least three months. To take part, your diagnosis must be confirmed by past camera tests of the bowel (endoscopy) and tissue samples. Your colitis must also be currently moderately to severely active, affecting at least 15 centimetres of the lower bowel.

The study is meant for people whose condition has not improved enough with standard treatments, such as steroids, immune-suppressing medicines, or targeted biologic therapies, or who could not tolerate them due to side effects. However, you cannot join if you have already tried three or more different types of advanced biologic therapies.

People with other types of bowel conditions, such as Crohn's disease, cannot take part. You will also be excluded if you have had serious bowel complications (like toxic megacolon or severe blockages) or if you have previously taken specific gut-targeted medicines called integrin blockers, such as vedolizumab.

Könnte diese Studie für Sie geeignet sein?

Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.

  1. You are between 18 and 75 years of age.
  2. You have had diagnosed ulcerative colitis symptoms for at least 90 days.
  3. Your colitis is currently moderately to severely active.
  4. Previous colitis treatments (like steroids or biologics) did not work well or caused side effects.
  5. You have never taken vedolizumab or similar integrin medicines.
  6. You have ulcerative colitis, not Crohn's disease.
Beantworten Sie jede Frage, um Ihr Ergebnis zu sehen.

Was beinhaltet die Teilnahme?

If you decide to join, you will be assigned to a treatment group by chance. You will receive either emvistegrast or a dummy medicine (placebo). You will need to attend regular clinic visits at the hospital so the medical team can monitor your health. These visits will involve health checks, blood and stool tests, and camera examinations of your bowel (endoscopies) to see if your gut lining is healing. The primary part of the study checks your progress at 12 weeks, with additional follow-up visits to ensure your safety. All trial medicines, clinic appointments, and tests are provided at no cost to you.

Potenzielle Risiken und Vorteile

Taking part may help improve your ulcerative colitis symptoms and gut healing, and you will receive close, expert medical care throughout the trial. However, there is no guarantee that the treatment will help, and you might receive a placebo without any active medicine. Like any new drug, emvistegrast may cause side effects, which the study team will explain to you before you start. Your participation is entirely voluntary, and you are free to leave the trial at any point without it affecting your standard NHS care.

Locations (181)

  • Onyx Clinical Research (Clinic Location)
    Verifizierte Postleitzahl
    Peoria, United States
  • Om Research LLC
    Verifizierte Postleitzahl
    Camarillo, United States
  • VVCRD Research
    Verifizierte Postleitzahl
    Garden Grove, United States
  • 310 Clinical Research
    Verifizierte Postleitzahl
    Inglewood, Vereinigte Staaten
  • US San Diego Health System
    Verifizierte Postleitzahl
    La Jolla, Vereinigte Staaten
  • Om Research LLC
    Verifizierte Postleitzahl
    Lancaster, United States
  • UCSF Benioff Children's Hospital Oakland
    Verifizierte Postleitzahl
    Oakland, Vereinigte Staaten
  • University Of California, Davis
    Verifizierte Postleitzahl
    Sacramento, Vereinigte Staaten
  • SDG Clinical Research, LLC
    Verifizierte Postleitzahl
    San Diego, Vereinigte Staaten
  • Acclaim Clinical Research
    Verifizierte Postleitzahl
    San Diego, Vereinigte Staaten
  • Peak Gastroenterology Associates
    Verifizierte Postleitzahl
    Colorado Springs, United States
  • Peak Gastroenterology Associates
    Verifizierte Postleitzahl
    Colorado Springs, United States

Häufige Fragen

What is a placebo and why is it used?

A placebo looks just like the real medicine but contains no active ingredients. It is used so researchers can clearly tell whether any improvements or side effects are truly caused by the study drug.

Will I have to pay for the study treatment?

No. The trial medicine, tests, and doctor visits are provided free of charge, and you may also receive help to cover your travel costs.

Can I stay on my regular ulcerative colitis medicines?

Some medications may be allowed at steady doses, while others may need to be paused. The study doctor will review all your current treatments to make sure it is safe for you to take part.

Wie lange werde ich an der Studie beteiligt sein?

The main goal of the study is to assess your response after 12 weeks of treatment, though the total time includes screening visits beforehand and safety checks afterwards.

What happens if my symptoms get worse during the trial?

Your health and comfort are the top priority. If your condition worsens, the medical team can provide rescue treatments or take you off the study to ensure you receive the best care.

Wie Sie mehr erfahren können

Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.

Diskussion

Community-Diskussion

Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.